NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions

HyperoxaluriaNephrolithiasis

Interventions

DRUG

ALLN-177

ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.

Trial Locations (4)

11042

North Shore Long Island Jewish Health System, Lake Success

44195

Cleveland Clinic, Cleveland

46202

Indiana University Physicians Urology, Indianapolis

02886

Omega Clinical Research, Warwick